ICON Reports 37% Increase in Revenues and 41% Increase in EPS. Backlog Exceeds $1 Billion for the First Time (NASDAQ:ICLR)

Highlights - Second Quarter 2007

* Second quarter net revenues increased 37% over the prior year,
to $147.0 million.

* Income from operations increased by 42%, to $16.1 million.

* Diluted earnings per share increased by 41%, to 45 cents.

* Record $230 million of net new business wins in the quarter,
representing a book-to-bill ratio of 1.6.

ICON (NASDAQ:ICLR), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, today reported its financial results for the second
quarter ended June 30, 2007.

Net revenues for the quarter were $147.0 million, representing a
36.9% increase over net revenues of $107.4 million for the same
quarter last year. Income from operations, after taking non-cash stock
compensation charge of $1.4 million, calculated in accordance with
SFAS 123(R), was $16.1 million or 10.9% of revenue, compared to $11.3
million or 10.6% for the same quarter last year. Net income was $13.3
million or 45 cents per share on a diluted basis, compared with $9.3
million or 32 cents per share last year.

Year-to-date, net revenues were $283.1 million, representing a
37.5% increase over the same period last year. Income from operations,
after taking non-cash stock compensation charge of $2.6 million
calculated in accordance with SFAS 123(R), was $30.8 million or 10.9%
of revenue, compared to $21.4 million or 10.4% last year. Net income
was $25.6 million or 86 cents per share, compared with $16.8 million
or 59 cents last year.

Days sales outstanding, comprising accounts receivable and
unbilled revenue less payments on account, were 53 days at June 30,
2007, a decrease from 59 days at March 31, 2007 and unchanged from 53
days at December 31, 2006.

For the quarter ended June 30, 2007, cash provided by operating
activities was $22.2 million and capital expenditure was $17.9
million. For the six months, cash flow from operating activities was
$19.4 million and capital expenditure was $30.4 million. As a result,
the company's cash and short-term investments, net of debt, amounted
to $91.1 million at June 30, 2007, compared to $97.9 million at
December 31, 2006.

"We are delighted with the second quarter's performance",
commented Chairman Dr. John Climax. "Revenue growth was very strong at
37%, and we made further progress in expanding margins which led to
net income growth of 43% and EPS growth of 41%. Excellent net bookings
of $230 million brought our backlog to over $1 billion, another
milestone in ICON's progress, giving us strong confidence in the
outlook for the remainder of the year"

"We recently completed the acquisition of DOCS International, a
leading European based clinical research staffing organisation, which
will be integrated with ICON's existing US based staffing business.
The combined operation will give our clients greater flexibility when
they run clinical projects internally, and give them access to a
global pool of talent through one vendor"

The company will hold its second quarter conference call today,
July 26, 2007 at 10:00 EST (15:00 Ireland & UK). This call and linked
slide presentation can be accessed live from our website at
http://www.iconclinical.com. A recording will also be available on the
website for 90 days following the call. In addition, a calendar of
company events, including upcoming conference presentations, is
available on our website, under "Investors". This calendar will be
updated regularly.

The statements made in this Press Release may contain
forward-looking statements that involve a number of risks and
uncertainties. In addition to the matters described in this Press
Release, the ability to maintain large client contracts or enter into
new contracts, maintain client relationships and the ability to manage
the opening of new offices, the integration of new business mergers
and acquisitions, as well as other risks and uncertainties detailed
from time to time in SEC reports filed by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements.

The financial information presented herein has been prepared in
accordance with U.S. GAAP.

ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specializes in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. ICON teams have successfully
conducted over 1,900 development projects and over 2,300 consultancy
engagements across all major therapeutic areas. ICON currently has
approximately 5,150 employees, operating from 63 locations in 33
countries. Further information is available at www.iconclinical.com.

-0-
*T
ICON plc

Consolidated Income Statements (Unaudited)

Three and Six Months ended June 30, 2007 and June 30, 2006
(Dollars, in thousands, except share and per share data)

Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
2007 2006 2007 2006

Gross Revenue 207,383 153,744 394,123 294,388

Subcontractor costs 60,336 46,308 110,987 88,457

---------- ---------- ---------- ----------
Net Revenue 147,047 107,436 283,136 205,931

Costs and expenses
Direct costs 83,875 60,014 162,432 114,718
Selling, general and
administrative 42,662 32,397 81,346 62,677
Depreciation and
amortization 4,450 3,689 8,606 7,134

---------- ---------- ---------- ----------
Total costs and expenses 130,987 96,100 252,384 184,529

Income from operations 16,060 11,336 30,752 21,402

Interest income (net) 1,019 938 2,063 1,585

---------- ---------- ---------- ----------
Income before provision of
income taxes 17,079 12,274 32,815 22,987

Provision for income taxes 3,758 2,943 7,186 6,073
Minority interest 6 34 48 76
---------- ---------- ---------- ----------

Net income 13,315 9,297 25,581 16,838
========== ========== ========== ==========

Net income per ordinary
share
Basic $0.46 $0.33 $0.89 $0.60
---------- ---------- ---------- ----------

Diluted $0.45 $0.32 $0.86 $0.59
---------- ---------- ---------- ----------

Weighted average number of
ordinary shares
Basic 28,684,201 28,265,490 28,624,350 28,174,762

Diluted 29,685,489 28,695,530 29,597,671 28,499,356
*T

-0-
*T

ICON plc

Summary Balance Sheet Data

June 30, 2007 and December 31, 2006
(Dollars, in thousands)

June 30, December 31,
2007 2006
(Unaudited) (Audited)
Cash and short-term investments 107,042 102,861
Short-term debt (15,947) (5,000)
Net cash 91,095 97,861

Accounts receivable 105,983 108,216
Unbilled revenue 104,740 89,977
Payments on account (87,619) (90,394)
Total 123,104 107,799

Working Capital 169,744 160,321

Total Assets 521,929 476,341

Shareholder's Equity 337,479 302,738
*T